Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Genmab A/S ADR
(NQ:
GMAB
)
28.38
+0.25 (+0.89%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Genmab A/S ADR
< Previous
1
2
3
4
5
6
Next >
10 Health Care Stocks With Whale Alerts In Today's Session
October 21, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Kura Oncology Stock Shows Improved Relative Strength; Still Shy Of Benchmark
October 14, 2022
In a welcome move, Kura Oncology stock saw its Relative Strength Rating improve from 69 to 75 on Wednesday.
Via
Investor's Business Daily
Amgen Stock Shows Market Leadership With Jump To 90 RS Rating
October 12, 2022
On Wednesday, Amgen stock hit a key technical milestone, with its Relative Strength Rating upgraded to 90, a rise from 78 the day before.
Via
Investor's Business Daily
BioCryst Pharmaceuticals Stock Shows Rising Relative Strength
October 10, 2022
On Monday, BioCryst Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 90 to 93.
Via
Investor's Business Daily
Pacira Pharmaceuticals Stock Shows Rising Relative Strength
October 07, 2022
On Friday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 69 to 73.
Via
Investor's Business Daily
HC Wainwright Is Bullish On This Multiple Myeloma Focused Stock
August 22, 2022
Via
Benzinga
Where Genmab Stands With Analysts
August 11, 2022
Genmab (NASDAQ:GMAB) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Genmab, BioNTech Join Forces For Cancer Immunotherapy Candidates
August 05, 2022
Via
Benzinga
Seagen, Zai Lab Ink Regional Strategic Licensing Agreement For Cervical Cancer Treatment
September 27, 2022
Via
Benzinga
Pain Therapeutics Stock Shows Rising Price Performance With Jump To 97 RS Rating
September 23, 2022
Pain Therapeutics sees its Relative Strength Rating enter the elite 90-plus level.
Via
Investor's Business Daily
Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90
September 14, 2022
Akero Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 73 to 99.
Via
Investor's Business Daily
Sage Therapeutics Stock Scores Relative Strength Rating Upgrade
September 09, 2022
On Friday, Sage Therapeutics stock received a positive adjustment to its Relative Strength (RS) Rating, from 86 to 91.
Via
Investor's Business Daily
Amylyx Pharmaceuticals Stock Sees Relative Strength Rating Rise To 98
September 09, 2022
Amylyx Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating improve to 98, up from 83 the day before.
Via
Investor's Business Daily
Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
September 02, 2022
Agios Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an increase from 65 to 93.
Via
Investor's Business Daily
Where Genmab Stands With Analysts
June 24, 2022
Analysts have provided the following ratings for Genmab (NASDAQ:GMAB) within the last quarter:
Via
Benzinga
AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial
June 13, 2022
Via
Benzinga
Analyst Ratings for Genmab
May 12, 2022
Within the last quarter, Genmab (NASDAQ:GMAB) has observed the following analyst ratings:
Via
Benzinga
Legend Biotech Stock Joins Elite Club Of Stocks With RS Ratings Over 90
September 01, 2022
On Thursday, Legend Biotech stock had its Relative Strength (RS) Rating upgraded to 91, up from 87 a day earlier.
Via
Investor's Business Daily
Golden Cross Appears Before Genmab Investors
August 31, 2022
If history is any guide, there may be good fortune ahead for shares of Genmab (NASDAQ:GMAB). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the...
Via
Benzinga
Intercept Pharmaceutical Stock Shows Market Leadership; Earns 92 RS Rating
August 30, 2022
On Tuesday, Intercept Pharmaceutical stock had its Relative Strength Rating upgraded to 92, up from 89 a day earlier.
Via
Investor's Business Daily
Relay Therapeutics Stock Shows Market Leadership With Jump To 94 RS Rating
August 25, 2022
Relay Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 84 to 94.
Via
Investor's Business Daily
Kymera Therapeutics Stock Scores Rising Relative Price Strength
August 22, 2022
Kymera Therapeutics stock hit a key performance benchmark, with its Relative Strength Rating upgradedjulie mak to 94.
Via
Investor's Business Daily
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
August 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
AbbVie To Submit European Application For Epcoritamab In Lymphoma Setting Later In 2022
July 18, 2022
Via
Benzinga
Is AbbVie Stock A Buy As Humira Biosimilar Rivals Loom?
July 07, 2022
Is AbbVie stock a buy today with its biggest medicine, Humira, soon to face biosimilar rivals in the U.S.? Is AbbVie stock a buy today
Via
Investor's Business Daily
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
July 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022
June 24, 2022
Upgrades
Via
Benzinga
Johnson & Johnson Stock: A Rare Bright Spot in the Market
May 14, 2022
JNJ stock is up on the year thanks in part to its steadily rising dividend, which investors covet during the current market volatility.
Via
InvestorPlace
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
May 11, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022
May 02, 2022
Upgrades
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.